Prospective case series have reported mixed efficacy profiles in patients treated with [177Lu]Lu-PSMA therapy for ACC, but treatment has been well tolerated with rapid relief of tumour-associated discomfort [94,95]. This evidence concerns the gene FOLH1 and adrenal cortex carcinoma.